|
All adverse events reported by frequency >5% |
||
| FPV/r 1400/100 mg + TDF/FTC QD N = 53 |
ATV/r 300/100 mg + TDF/FTC QD N = 53 |
|
|
|
||
| Diarrhea |
28 (53%) |
13 (25%) |
| Blood bilirubin increased |
0 |
16 (30%) |
| Nausea |
8 (15%) |
6 (11%) |
| Rash |
9 (17%) |
5 (9%) |
| Fatigue |
6 (11%) |
7 (13%) |
| Headache |
5 (9%) |
3 (6%) |
| Hyperbilirubinemia |
0 |
8 (15%) |
| Cough |
4 (8%) |
3 (6%) |
| Nasopharyngitis |
3 (6%) |
4 (8%) |
| Upper respiratory tract infection |
2 (4%) |
4 (8%) |
| Arthralgia |
0 |
5 (9%) |
| Insomnia |
2 (4%) |
3 (6%) |
| Ocular icterus |
0 |
5 (9%) |
| Syphilis |
5 (9%) |
0 |
| Depression |
3 (6%) |
1 (2%) |
| Herpes zoster |
1 (2%) |
3 (6%) |
| Dizziness |
3 (6%) |
0 |
| Jaundice |
0 |
3 (6%) |
| Paresthesia |
3 (6%) |
0 |
Smith et al. AIDS Research and Therapy 2008 5:5 doi:10.1186/1742-6405-5-5 |
||